About: Investigation of Griffithsin's Interactions with Human Cells Confirms Its Outstanding Safety and Efficacy Profile as a Microbicide Candidate

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Investigation of Griffithsin's Interactions with Human Cells Confirms Its Outstanding Safety and Efficacy Profile as a Microbicide Candidate Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Investigation of Griffithsin's Interactions with Human Cells Confirms Its Outstanding Safety and Efficacy Profile as a Microbicide Candidate
Creator	Kouokam, J Schols, D Huskens, D Johannemann, A Riedell, S
Source	Medline; PMC
abstract	Many natural product-derived lectins such as the red algal lectin griffithsin (GRFT) have potent in vitro activity against viruses that display dense clusters of oligomannose N-linked glycans (NLG) on their surface envelope glycoproteins. However, since oligomannose NLG are also found on some host proteins it is possible that treatment with antiviral lectins may trigger undesirable side effects. For other antiviral lectins such as concanavalin A, banana lectin and cyanovirin-N (CV-N), interactions between the lectin and as yet undescribed cellular moieties have been reported to induce undesirable side effects including secretion of inflammatory cytokines and activation of host T-cells. We show that GRFT, unlike CV-N, binds the surface of human epithelial and peripheral blood mononuclear cells (PBMC) through an exclusively oligosaccharide-dependent interaction. In contrast to several other antiviral lectins however, GRFT treatment induces only minimal changes in secretion of inflammatory cytokines and chemokines by epithelial cells or human PBMC, has no measureable effect on cell viability and does not significantly upregulate markers of T-cell activation. In addition, GRFT appears to retain antiviral activity once bound to the surface of PBMC. Finally, RNA microarray studies show that, while CV-N and ConA regulate expression of a multitude of cellular genes, GRFT treatment effects only minimal alterations in the gene expression profile of a human ectocervical cell line. These studies indicate that GRFT has an outstanding safety profile with little evidence of induced toxicity, T-cell activation or deleterious immunological consequence, unique attributes for a natural product-derived lectin.
has issue date	2011-08-02(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0022635
bibo:pmid	21829638
has license	cc0
sha1sum (hex)	24e8a04adeb7f1142768d4de1e10d8ac48afcd03
schema:url	https://doi.org/10.1371/journal.pone.0022635
resource representing a document's title	Investigation of Griffithsin's Interactions with Human Cells Confirms Its Outstanding Safety and Efficacy Profile as a Microbicide Candidate
has PubMed Central identifier	PMC3149051
has PubMed identifier	21829638
schema:publication	PLoS One
resource representing a document's body	covid:24e8a04adeb7f1142768d4de1e10d8ac48afcd03#body_text
is schema:about of	named entity 'INVESTIGATION' named entity 'lectin' named entity 'activation' named entity 'lectin' named entity 'studies' named entity 'viability' named entity 'undescribed' named entity 'T-cell' named entity 'SAFETY' named entity 'ITS' named entity 'EXPRESSION' named entity 'LECTINS' named entity 'DERIVED' named entity 'INTERACTIONS' named entity 'ADDITION' named entity 'HUMAN' named entity 'SECRETION' named entity 'PROFILE' named entity 'BOUND' named entity 'THESE' named entity 'CYTOKINES' named entity 'REPORTED' named entity 'INDUCE' named entity 'DISPLAY' named entity 'TREATMENT' named entity 'IMMUNOLOGICAL' named entity 'IN VITRO ACTIVITY' named entity 'PROFILE' named entity 'GLYCOPROTEINS' named entity 'EPITHELIAL' named entity 'DENSE' named entity 'HAVE' named entity 'DOES NOT' named entity 'ACTIVATION' named entity 'ALGAL' named entity 'INFLAMMATORY' named entity 'THEIR' named entity 'MARKERS' named entity 'TRIGGER' named entity 'EFFICACY' named entity '27S' named entity 'CONFIRMS' named entity 'INTERACTIONS' named entity 'HUMAN CELLS' named entity 'OUTSTANDING' named entity 'STUDIES' named entity 'ECTOCERVICAL' named entity 'CLUSTERS' named entity 'RETAIN' named entity 'CONSEQUENCE' named entity 'UNIQUE' named entity 'PERIPHERAL BLOOD MONONUCLEAR CELLS' named entity 'MULTITUDE' named entity 'RNA MICROARRAY' named entity 'LECTIN' named entity 'ATTRIBUTES' named entity 'INTERACTION' named entity 'ENVELOPE' named entity 'EPITHELIAL CELLS' named entity 'MINIMAL' named entity 'PROTEINS' named entity 'NATURAL' named entity 'T-CELLS' named entity 'OUTSTANDING' named entity 'RED' named entity 'VIRUSES' named entity 'CYANOVIRIN-N' named entity 'CONTRAST' named entity 'ALTERATIONS' named entity 'GENE EXPRESSION PROFILE' named entity 'CELL VIABILITY' named entity 'PBMC' named entity 'ON CELL' named entity 'GLYCANS' named entity 'CONCANAVALIN A' named entity 'SIDE EFFECTS' named entity 'EVIDENCE OF'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software